Related Experiment Video
Updated: Jun 18, 2026
09:11
Screening for Thermotoga maritima Membrane-Bound Pyrophosphatase Inhibitors
Published on: November 23, 2019
DPP-4 inhibitors in clinical practice
Anna I Palalau1, Abd A Tahrani, Milan K Piya
1Department of Diabetes and Endocrinology, Heart of England NHS Foundation Trust, Birmingham, UK.
Postgraduate Medicine
|November 27, 2009
Summary
Dipeptidyl peptidase-4 (DPP-4) inhibitors offer effective type 2 diabetes management by improving glycemic control without causing hypoglycemia or weight gain. This review explores their role in treating type 2 diabetes.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Disorders
Background:
- Type 2 diabetes is a global health issue requiring effective management for glycemic control.
- Progressive nature of type 2 diabetes necessitates combination therapies, often with side effects like hypoglycemia and weight gain.
- Incretin-based therapies represent a novel approach to antidiabetes treatment.
Purpose of the Study:
- To review the scientific basis of incretin-based therapy.
- To evaluate the efficacy and role of dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes management.
Main Methods:
- Review of scientific literature on incretin-based therapies.
- Analysis of clinical evidence for DPP-4 inhibitors (sitagliptin, saxagliptin, vildagliptin).
Main Results:
- DPP-4 inhibitors effectively lower glycated hemoglobin, fasting, and postprandial glucose levels.
- These agents demonstrate a low incidence of hypoglycemia and do not cause weight gain.
- DPP-4 inhibitors are effective as monotherapy or in combination treatments.
Conclusions:
- DPP-4 inhibitors are a valuable addition to the pharmacologic options for type 2 diabetes.
- Their favorable side effect profile and efficacy make them a key treatment strategy.
- Further development and availability of DPP-4 inhibitors are anticipated.
Related Concept Videos
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...